newsfilter
← Latest News
GlobeNewswire·

KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

Upon IND clearance, KemPharm anticipates initiating KP1077 Phase 2 IH trial as early as the second half of 2022 CELEBRATION, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a specialty pharmaceutical